Microsoft (NASDAQ:MSFT – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a report issued on Monday,Benzinga reports. They currently have a $625.00 target price on the software giant’s stock. Wedbush’s price target suggests a potential upside of 28.62% from the company’s previous close. MSFT has been the subject […]

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $46.00 price target on the stock. Wedbush’s target price points to a potential upside of 8.39% from the stock’s current price. Other research analysts have […]